MENTINOVA, INC. logo

MENTINOVA, INC.

MentiNova, Inc. is developing an oral medication that could alleviate L-Dopa Induced Dyskinesia in patients with Parkinsons disease. MentiNovas strategy is to use a drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in Parkinsons disease patients.

MentiNova was co-founded by M. Maral Mouradian, William Dow Lovett Professor of Neurology and Director, Center for Neurodegenerative and Neuroimmunologic Diseases at Rutgers Biomedical and Health Sciences-Robert Wood Johnson Medical School.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://mentinova.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
120 Albany Street Tower II, Suite 850,New Jersey,8901
NEW BRUNSWICK
United States
Email
Contact Number
+1 908-731-6610

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/mentinova-inc.” connections=”true” suffix=””]

In Jan 2013, MentiNova, Inc. complete seed financing and raised $5 Mn. The financing was led by Foundation Venture Capital Group.